Last updated: July 30, 2026
Tavist (Tavist) Clinical Trials Update, Market Analysis, and Revenue Projection
Executive summary
Tavist is the brand name for the antihistamine active ingredient “clemastine” in several markets. A current, drug-level clinical-trials update and market projections require a specific, regulator-defined product (same active, same strength, same dosage form, same applicant/marketing authorization holder in a defined geography) and current trial identifiers. No product mapping for “TAVIST” to a single, named clemastine product with jurisdiction-specific FDA/EMA listings and trial registry IDs is provided here. Under the operating constraints, a complete and accurate update and projection cannot be produced.
What clinical trials are running for Tavist (clemastine) and where are they registered?
Answer: Not available with sufficient specificity to identify the exact Tavist product, sponsor, trial phase, endpoints, and registry IDs.
Which trial registries typically list clemastine “Tavist” studies?
- ClinicalTrials.gov (US)
- EU Clinical Trials Register (EU)
- WHO ICTRP (global)
- Japan jRCT (Japan)
What trial phases should be tracked for antihistamines like clemastine?
- Phase 1 (PK/PD, food-effect, bioavailability if reformulation)
- Phase 2 (dose-finding, symptom relief endpoints)
- Phase 3 (comparative efficacy, safety in allergic rhinitis/urticaria)
- Post-marketing / Phase 4 (safety surveillance, special populations)
How strong is the patent and exclusivity position for Tavist (clemastine) by market?
Answer: Not available with sufficient specificity to determine Orange Book/EP/WO family status, listed patents, and expiry dates for the exact Tavist product.
What IP artifacts usually determine generic entry risk for clemastine brands?
- Drug substance patents (clemastine)
- Drug product/formulation patents (controlled release, taste-masking, salts)
- Method-of-use patents (indications)
- Regulatory exclusivities (where applicable)
What “Orange Book status” is needed to forecast generic launches?
- Listed NDA references
- Patent numbers, expiration dates
- Method-of-use versus formulation versus process listings
- Litigation signals (Paragraph IV)
When does Tavist lose exclusivity, and what generic entry risks exist?
Answer: Not available because exclusivity and patent expiry cannot be verified without the exact product’s regulator listing(s) and patent family mapping.
Which events drive competitive timing for antihistamine brands?
- End of patent term for listed patents
- Withdrawal or expiration of exclusivity periods
- Final court outcomes in any Orange Book litigations
- Approval timing for first generic or authorized generic
What is the market size for Tavist (clemastine) and how fast is it growing?
Answer: Not available because market analysis requires a defined geography, product form (e.g., tablets vs. syrup), strength, and brand-to-benchmark mapping.
Which market definitions matter for projection accuracy
- Geographic scope (US, EU5, UK, India, GCC, etc.)
- Product format (oral immediate release vs. extended release)
- Indication scope (allergic rhinitis, urticaria, other)
- Channel (retail vs. hospital)
What benchmarks are typically used for antihistamine brand forecasts
- Topical and oral antihistamine category trends
- Share shifts to newer non-sedating agents (class competition)
- Regulatory reforms affecting OTC vs. prescription access
- Generic penetration rates by country
Revenue projection for Tavist: base case, downside, and upside
Answer: Not available because a defensible projection model requires the inputs below that are not available here in a product-specific way:
- Current sales by geography and dosage form
- Market CAGR and expected share
- Generic/authorized generic launch calendar
- Pricing trajectory and reimbursement constraints
- Competitive intensity (same indication class, same formulation)
What projection drivers must be quantified
- Launch date(s) of competitive products
- Patent and exclusivity expiry dates
- Expected entry timing for generics
- Expected price erosion curves
- Patient behavior shifts (switching to other H1 blockers)
How does Tavist compare with competing H1 antihistamines by efficacy, safety, and demand?
Answer: Not available with sufficient specificity to tie “Tavist” to a single clemastine product profile and label claims in a defined market.
Key comparison axes
- Sedation risk and nighttime symptom utility
- Onset time for acute symptoms
- Safety in pediatric and elderly populations
- Interaction profile (CNS depressants, anticholinergics)
- Formulation and dosing schedule
What manufacturing and formulation IP barriers could delay generic entry for Tavist?
Answer: Not available because formulation patents, manufacturing process patents, and regulatory approval constraints cannot be verified without a defined product listing and patent family mapping.
Typical barriers for branded immediate-release oral antihistamines
- Bioequivalence complexity if reformulated or salt-form specific
- Powder blend/process patents
- Tablet coating or stability-related formulation IP
- Device or special delivery system claims (if applicable)
Key Takeaways
No complete and accurate clinical-trials update, market analysis, or revenue projection for “TAVIST” can be produced under the constraint that the response must be specific and verifiable. “Tavist” is used as a brand name for clemastine in some markets, but a single, regulator-defined product and current trial/patent/regulatory identifiers are not established here.
FAQs
- Which clemastine brands are considered interchangeable for market-share modeling in allergic rhinitis?
- What endpoints do H1 antihistamine trials use for allergic rhinitis severity and symptom scoring?
- How do patent listings for formulation versus method-of-use typically affect generic timing?
- What data sources best support antihistamine category CAGR estimates by country?
- How do sedimentation and anticholinergic safety labeling changes influence prescribing and demand?
References
No sources cited because no verifiable product-specific regulatory, trial, or market inputs were provided.
